Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

Van Gelder M, De Wreede LC, Bornhaeuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispizua A, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, Van Biezen A, Henseler A, Schoenland S, Kroeger N, Schetelig J (2017)

Publication Type: Journal article

Publication year: 2017


Book Volume: 52

Pages Range: 372-380

Journal Issue: 3

DOI: 10.1038/bmt.2016.282


Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.

Involved external institutions

Maastricht University Medical Center (UMC+) NL Netherlands (NL) DKMS Deutsche Knochenmarkspenderdatei DE Germany (DE) Technische Universität Dresden DE Germany (DE) Universitätsklinikum Leipzig DE Germany (DE) General University Hospital in Prague / Všeobecná Fakultní Nemocnice v Praze (VFN) CZ Czech Republic (CZ) Rigshospitalet DK Denmark (DK) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Centre Hospitalier Lyon Sud (CHLS) FR France (FR) Paracelsus-Elena-Klinik Kassel DE Germany (DE) Universitätsklinikum Ulm DE Germany (DE) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust GB United Kingdom (GB) Universitätsklinikum Heidelberg DE Germany (DE) Erasmus University Medical Center (MC) NL Netherlands (NL) Centre hospitalier universitaire de Brest (CHRU Brest) FR France (FR) Nottingham University Hospitals GB United Kingdom (GB) Albert-Ludwigs-Universität Freiburg DE Germany (DE) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Institute of Hematology and Blood Transfusion (IHBT) / Ústav hematologie a krevní transfuze (ÚHKT) CZ Czech Republic (CZ) Hospital Clínic de Barcelona ES Spain (ES) CRCM Centre de Recherche en Cancérologie de Marseille FR France (FR) Helsinki University Central Hospital (HUCH) / Helsingin seudun yliopistollinen keskussairaala (HYKS) FI Finland (FI) Nantes University Hospital / Centre hospitalier universitaire de Nantes (CHU) FR France (FR) Complejo Hospitalario de Salamanca / Complejo Asistencial Universitario de Salamanca ES Spain (ES) Leiden University NL Netherlands (NL) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE)

How to cite


Van Gelder, M., De Wreede, L.C., Bornhaeuser, M., Niederwieser, D., Karas, M., Anderson, N.S.,... Schetelig, J. (2017). Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 52(3), 372-380. https://doi.org/10.1038/bmt.2016.282


Van Gelder, M., et al. "Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation." Bone Marrow Transplantation 52.3 (2017): 372-380.

BibTeX: Download